Skip to content
Use caution Drug recall · FDA · Published July 2, 2012

Hospira Recalls Carboplatin Injection Due to pH Specification Failure

Hospira Inc. recalls specific lots of Carboplatin Injection (10 mg/mL) due to failed pH specifications. Check lot numbers and expiration dates for affected vials.

🇺🇸 FDA recall #D-1648-2012DrugHospira ›
Take action

Contact the company

Recalling firmHospira Inc.275 N Field Dr · Lake Forest, IL 60045-2579
✎ GovInfoNow plain-language explainer

Hospira Inc. is recalling specific lots of Carboplatin Injection, a chemotherapy drug, because the manufacturing process resulted in product that did not meet pH specifications. The recall covers both Hospira-branded and Novaplus-branded multi-dose vials distributed nationwide and in Puerto Rico. No remedy or return instructions are currently listed in the record. Read more at govinfonow.com/recall/48652-hospira-inc-recalls-carboplatin-injection-10-mg-ml-a-5.

Source Summary by GovInfoNow · govinfonow.com/recall/48652-hospira-inc-recalls-carboplatin-injection-10-mg-ml-a-5 · Updated October 13, 2026 · FDA enforcement record: FDA #D-1648-2012

Cite this page

“Hospira Recalls Carboplatin Injection Due to pH Specification Failure.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/48652-hospira-inc-recalls-carboplatin-injection-10-mg-ml-a-5. Based on FDA recall #D-1648-2012 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1648-2012%22&limit=1).

The FDA announced on July 2, 2012, that Hospira Inc. voluntarily recalled Carboplatin Injection due to failed pH specifications. The recall affects specific lots of 5 mL and 45 mL multi-dose vials distributed nationwide and in Puerto Rico.

How to tell if you have it

  • Carboplatin Injection, 10 mg/mL
  • NDC 61703-339-18 (Hospira label), lot Y031654AB, expiration APR2013
  • NDC 61703-360-18 (Novoplus label), lot Y031654AA, expiration APR2013
  • NDC 61703-339-50 (Hospira label), lots Y041711AA and Y061711AB, expirations DEC 2012 and FEB 2013
  • NDC 61703-360-50 (Novoplus label), lot Y061711AA, expiration FEB 2013

The hazard

The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH. The FDA classified this Class III recall as voluntary and firm-initiated.

Context

GovInfoNow's records show Hospira Inc. has 108 other recalls on record since 2012-04-05. Other recent recalls of similar products include Cipla Diclofenac Gel Recall: Failed PH Specifications Risk (2025-12-22), Cipla Recalls Fosfomycin Tromethamine Granules Due to Impurities (2026-09-18), and Cipla Phytonadione Injectable Emulsion Recall: Stability Issues (2025-10-31).

How to tell if you have this one

Check your vials for the following details: Product is Carboplatin Injection, 10 mg/mL. Look for NDC numbers 61703-339-18, 61703-360-18, 61703-339-50, or 61703-360-50. Affected lot numbers include Y031654AB (exp APR2013), Y031654AA (exp APR2013), Y041711AA (exp DEC2012), Y061711AB (exp FEB2013), and Y061711AA (exp FEB2013).

  • Brand
    Hospira
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Identify Affected Vials

    Check the labels on your Carboplatin Injection vials against the NDC numbers and lot numbers listed in the recall record.

  2. Contact Healthcare Provider

    If you have an affected lot, contact your doctor or pharmacist immediately to discuss next steps for your treatment.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 5.1 years after the firm started it.

1. Firm started the recall: Jul 2, 201212. FDA classified it Class III: Aug 16, 201223. Published in FDA’s Enforcement Report: Aug 22, 201234. FDA terminated the recall: Jul 24, 2017420122017
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1648-2012 (July 2, 2012) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1648-2012 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA